ライフサイエンスコーパス: anti-tumor effect

1 ) iu of rAd resulted in augmentation of this anti-tumor effect.

2 and MEK/ERK, as potential mechanisms of its anti-tumor effect.

3 the ability of the elicited Abs to exert an anti-tumor effect.

4 because CD4 depletion does not diminish the anti-tumor effect.

5 yte infiltration of tumors and showed strong anti-tumor effects.

6 utically appealing, but has had very limited anti-tumor effects.

7 aged mice receiving IT displayed significant anti-tumor effects.

8 to an enhancement of its anti-angiogenic and anti-tumor effects.

9 modulate infused T-cell responses to enhance anti-tumor effects.

10 ization, and down-regulation with subsequent anti-tumor effects.

11 ntibodies, and Sindbis viral vectors confers anti-tumor effects.

12 alpha-CD40 alone mediated partial transient anti-tumor effects.

13 expression imparts resistance to celecoxib's anti-tumor effects.

14 ivering potentially curative immune-mediated anti-tumor effects against a number of different hematol

15 cholesterol reducing drugs, statins, exhibit anti-tumor effects against cancer stem cells and various

16 RRM domain antibodies are associated with an anti-tumor effect and paraneoplastic encephalomyelitis,

17 Moreover, IL-21 has potent anti-tumor effects and is implicated in the development

18 The anti-tumor effects and leukocyte recruitment mediated by

19 tral role for iNKTs in promoting RLI-induced anti-tumor effects and suggest that this pathway involve

20 nti-C6VL TCR Abs into na ive mice had modest anti-tumor effects and was not sufficient to prevent tum

21 evels of tumor PGE(2), suggesting that their anti-tumor effects are directly associated with the inhi

22 s not profound enough to achieve comparative anti-tumor effects as EE.

23 larly evident in vivo and likely limited the anti-tumor effects, as confirmed by re-initiation of tum

24 l effector cells may also be involved in the anti-tumor effect at higher local concentrations of IL-1

25 ssays showed that Alox5 exhibited a moderate anti-tumor effect both in vitro and in vivo.

26 BKM120 or LEE011 yielded more than additive anti-tumor effects both in vitro and in vivo in a melano

27 , simvastatin has also been reported to have anti-tumor effect, but the underlying mechanism is large

28 acid (UA) has proved to have broad-spectrum anti-tumor effects, but its poor water solubility and in

29 that DOX-HK-MPEG-PCL micelles improved Dox's anti-tumor effect by enhancing tumor cell apoptosis, sup

30 ound that gammaSI enhanced miR-34a-dependent anti-tumor effects by activating the extrinsic apoptotic

31 changes predicted T-cell engraftment, while anti-tumor effects correlated with neutrophil-to-lymphoc

32 ession, however, has differing pro-tumor vs. anti-tumor effects, depending on the cancer types.

33 se, sequential regimen that imparts a robust anti-tumor effect for non-small-cell lung cancer (NSCLC)

34 L responses capable of producing therapeutic anti-tumor effects (i.e., prolongation of survival, tumo

35 However, the mechanism of AR's anti-tumor effect in breast cancer is still not fully un

36 myrcene- induced a statistically significant anti-tumor effect in mice but not alpha-pinene, myrcene

37 ells are not likely to mediate a significant anti-tumor effect in vivo.

38 n of cGMP-dependent protein kinase (PKG) has anti-tumor effects in colon cancer cells but the mechani

39 Although they show anti-tumor effects in culture and in mouse models, these

40 ing of these agents, as they generate potent anti-tumor effects in experimental animals.

41 trast, IL-1H4 was able to confer substantial anti-tumor effects in NKT-deficient mice.

42 ore, miR-497 exhibited anti-angiogenesis and anti-tumor effects in the VEGFR2-luc breast tumor model

43 Potent and durable anti-tumor effects in TNBC xenografts, including complet

44 nistration of anti-CD40 antibodies has shown anti-tumor effects in vivo through a variety of mechanis

45 The combination demonstrated synergistic anti-tumor effects in vivo without toxicity and in the f

46 nd human T cells, which results in augmented anti-tumor effects in vivo.

47 MSC-delivered recombinant TRAIL has profound anti-tumor effects in vivo.

48 uses anti-proliferative effects in vitro and anti-tumor effects in vivo.

49 f recipient NK1.1(+) cells led to loss of an anti-tumor effect induced by RLI in mixed bone marrow ch

50 y, specific activation of iNKTs enhanced the anti-tumor effect induced by RLI.

51 Second, partial abrogation of the anti-tumor effect is induced with anti-CD40L antibodies

52 of 14 evaluable patients showed evidence of anti-tumor effects lasting up to 26 months, based on phy

53 nce and immuno-response, we investigated the anti-tumor effect of a glutamine analog (6-diazo-5-oxo-L

54 etion of CD20+ B cells partially blocked the anti-tumor effect of APCP and significantly reduced the

55 -bearing mice receiving anti-IL-17A mAb, the anti-tumor effect of APCP was ablated.

56 ified two bacterial species potentiating the anti-tumor effect of cyclophosphamide that are kept in c

57 esence of essential factors required for the anti-tumor effect of GM-CSF.

58 the critical role of FasL regulation in the anti-tumor effect of HDACIs.

59 uncovering a novel mechanism underlying the anti-tumor effect of HDACIs.

60 We also provide evidence for anti-tumor effect of IGFBP-3R in vivo using prostate and

61 In this study, we investigated the anti-tumor effect of MLN4924 in human clear cell renal c

62 n image-based assessment of distribution and anti-tumor effect of nano- and macromolecular systems.

63 Herein, we characterize the anti-tumor effect of rapamycin in a mouse model of T-cel

64 The greatest anti-tumor effect of single injection of Doxil(R) was ac

65 The anti-tumor effect of vitamin D has been well recognized

66 to cancer initiation, our work demonstrates anti-tumor effects of 2HG in inhibiting proliferation/su

67 Herein, we characterize anti-tumor effects of a unique human CD4(+) helper T-cel

68 To better characterize the protective anti-tumor effects of alphabeta T cells, we examined the

69 RAIL-resistant malignancies sensitive to the anti-tumor effects of Apo2L/TRAIL in vitro and in vivo.

70 To investigate the anti-tumor effects of avicin D in cutaneous T-cell lymph

71 erapeutic drug has been shown to enhance the anti-tumor effects of cancer vaccines and adoptive cell

72 rived from these cells were resistant to the anti-tumor effects of digoxin, demonstrating that HIF-1

73 ibitor, has been demonstrated to enhance the anti-tumor effects of DNA damaging agents such as gemcit

74 ents a pharmacological target to enhance the anti-tumor effects of DNA damaging modalities in the tre

75 TAT1 may be an early step in the cooperative anti-tumor effects of IFN and RA.

76 data differentiate the mechanism for primary anti-tumor effects of IL-2/alpha-CD40 immunotherapy, whi

77 The described anti-tumor effects of indomethacin are evident whether i

78 he signaling network thought to diminish the anti-tumor effects of mTORC1 inhibition.

79 Therefore, our results indicated that the anti-tumor effects of photofrin based PDT was strongly a

80 thway has been highlighted as central to the anti-tumor effects of PKG.

81 ion and cancer growth but also abrogates the anti-tumor effects of PPARgamma and rosiglitazone.

82 and whose therapeutic targeting enhances the anti-tumor effects of radiotherapy.

83 nd its oncogenic activities and evaluate the anti-tumor effects of reducing IGF2 signaling.

84 mmary tumor development but also impairs the anti-tumor effects of rosiglitazone.

85 In this study, we investigated the anti-tumor effects of SAHA in CTCL cell lines and freshl

86 molecular target of SFN, which mediates the anti-tumor effects of SFN.

87 tivation of the STING pathway, enhancing the anti-tumor effects of STING agonists and radiotherapy.

88 ntation has provided evidence for the potent anti-tumor effects of T cells.

89 The anti-tumor effects of the CD4+ T cells required the pres

90 Therefore, the synergistic anti-tumor effects of type I IFNs and MSCs were achieved

91 Preclinical studies have demonstrated the anti-tumor effects of varied anti-angiogenic agents in s

92 extracellular fluid translated into a strong anti-tumor effect prolonging survival of mice bearing GD

93 of Rheb by FTI is responsible for the drug's anti-tumor effects, such that a farnesylation-independen

94 emically administered toxin produced greater anti-tumor effects than wild-type LT toward human xenogr

95 shRNA-mediated CDK9 inhibition led to robust anti-tumor effects that correlated with MYC expression l

96 ivery and magnetic hyperthermia, the in vivo anti-tumor effect under a low-frequency magnetic field u

97 es not necessarily translate to the enhanced anti-tumor effect unless it is accompanied by the tempor

98 The anti-tumor effect was diminished in mice deficient in CD

99 After irradiating with an NIR laser, a good anti-tumor effect was observed owing to the enhanced pho

100 were immune-deficient, it is likely that the anti-tumor effect was primarily through direct inhibitio

101 Anti-tumor effects were seen in both indolent and aggres

102 antibody resulted in only partial, transient anti-tumor effects whereas combined treatment with IL-2/

103 single injection of Combo NP had synergistic anti-tumor effects while the same molar ratio of combine

104 A novel approach to achieving anti-tumor effects without the risk of GVHD is suggested